Inactive Instrument

Idogen AB (publ)

Equities

IDOGEN

SE0014428561

Biotechnology & Medical Research

BioStock: Idogen has reached milestone in clinical trial preparations

December 07, 2021 at 04:04 am EST

Idogen has optimised the GMP manufacturing process in order to maximise the treatment effect of the cell therapy IDO 8 in patients with haemophilia A. The extensive optimisation work is now completed and Idogen is thus approaching the first clinical study with IDO 8. The company is about to submit a clinical trial application to the Medical Products Agency and plans to initiate the study during the second quarter of 2022.

Read the full article at biostock.se:

https://www.biostock.se/en/2021/12/idogen-has-reached-milestone-in-clinical-trial-preparations/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se

https://news.cision.com/idogen/r/biostock-idogen-has-reached-milestone-in-clinical-trial-preparations,c3467078

Latest news about Idogen AB (publ)

Certain Shares of Idogen AB are subject to a Lock-Up Agreement Ending on 12-JUL-2023.	23-07-11	CI
Idogen Delisted from Nasdaq First North Growth Market Amid Bankruptcy	23-07-10	MT
Cell Therapy Group Idogen Formally Files for Bankruptcy After Merger Talks Fail	23-07-07	MT
Idogen Mulls Sale of Proprietary Technology Platform Amid Looming Liquidation	23-05-30	MT
Idogen Mulls Sale of Proprietary Technology Platform Amid Looming Liquidation	23-05-30	MT
Idogen AB Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-09	CI
Idogen Discusses Reverse Takeover with Several Parties	23-04-28	CI
Idogen to Propose Liquidation at June Annual Meeting, Kicks Off Reverse Merger Talks	23-04-28	MT
Sweden's Idogen Warns of Liquidation if Capital Plan Fails; Shares Plunge 35%	23-04-18	MT
Idogen AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2022	23-02-24	CI
Idogen AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2022	23-02-24	CI
Idogen AB Reports Earnings Results for the Full Year Ended December 31, 2022	23-02-24	CI
Idogen AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-25	CI
Idogen AB Appoints Jan Holgersson to Its Board of Directors	22-11-21	CI
Idogen Chair Steps Down, Former Chairman To Take Up Role Again	22-11-02	MT
Idogen AB Announces Board Changes	22-11-01	CI
Sweden's Idogen Bags Last Tranche of EU Grant for Hemophilia Drug Study	22-10-17	MT
Idogen AB Announces First Patient Enters Idogen's Hemophilia Study Under the Ido 8 Program	22-10-13	CI
Idogen AB Sharpens Focus on its IDO 8 Program and Lowers Operating Expenditure	22-10-03	CI
Idogen AB to Commence the Phase I/IIa Clinical Trial of its Drug Candidate in the IDO 8 Program	22-10-03	CI
Idogen AB Announces Board Changes	22-09-27	CI
Idogen Wins Approval For Hemophilia Medication Study At Oslo University Hospital In Norway	22-09-21	MT
Idogen Receives Approval from the Regional Ethics Committee to Conduct Clinical Phase I/IIa Study	22-09-21	CI
Idogen Appoints Christina Herder as Acting CEO	22-09-13	CI
Redeye Updates Their Analysis of Idogen as Company Approaches Clinical Phase	22-09-05	CI

Chart Idogen AB (publ)

Duration

Period

More charts

Company Profile

Idogen AB is a Sweden-based company engaged in the healthcare industry. The Company is a research-driven entity developing a so called Tolerogenic Vaccine, a treatment concept for anti-drug antibodies, autoimmune diseases and transplant rejection. Its treatment is based on the patient's own dendritic cells (a type of white blood cell) and is taken out and reprogrammed in vitro and then given back to the patient. The Company is in pre-clinical phase and owns a platform technology, from which Idogen AB develops treatment for anti-drug antibodies, as well as autoimmune diseases that cannot be cured. In addition, the Company focuses on the transplantation market by reducing the need for immunosuppressive therapy after transplantation.

Sector

Biotechnology & Medical Research

Calendar

2024-05-28 - Q1 2024 Earnings Release (Projected)

More about the company

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
VERTEX PHARMACEUTICALS INCORPORATED	-2.31%	103B
REGENERON PHARMACEUTICALS, INC.	+0.56%	95.71B
ARGENX SE	+1.69%	22.02B
BIONTECH SE	-17.37%	20.9B
GENMAB A/S	-9.30%	17.85B
WUXI APPTEC CO., LTD.	-41.01%	16.21B
BEIGENE, LTD.	-14.85%	15.52B
NEUROCRINE BIOSCIENCES, INC.	+3.21%	13.86B
SAREPTA THERAPEUTICS, INC.	+33.54%	12.04B

Bio Therapeutic Drugs